IG
IRWD icon

ING Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

ING Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-24,981
Closed -$208K – 736
2013
Q2 		$208K Buy
+24,981
New +$303K ﹤0.01% 651

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ING Group's IRWD Position: Q3 2013 in Review

ING Group sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2013, closing a stake of 24,981 shares — an estimated $208K sold.

ING Group first reported a position in IRWD in Q2 2013 and held it in 1 quarter. The position peaked at $208K in Q2 2013. 124 funds tracked by Wall St. Rank hold IRWD as of Q3 2013.

  • ING Group reported no remaining Ironwood Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • ING Group sold 24,981 Ironwood Pharmaceuticals shares in Q3 2013, an estimated $208K.
  • ING Group first reported a position in Ironwood Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • ING Group's Ironwood Pharmaceuticals position peaked at $208K in Q2 2013.
  • 124 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2013.

Based on ING Group's 13F filing for Q3 2013, filed 13 Nov 2013.